Analytical Data
-
基因名
E7
- Application
-
别名
Protein E7
-
种属
Human papillomavirus type 16
-
表达系统
E. coli
-
标签
N- His & C- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P03129
-
表达区间
1-98aa
-
分子量
16.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The E7 protein, an oncoprotein derived from the human papillomavirus (HPV), has garnered significant attention in cancer research due to its pivotal role in the development of cervical cancer and other HPV-related malignancies. HPV infects epithelial cells, and the E7 protein disrupts normal cell cycle regulation by interfering with host cell tumor suppressor pathways, particularly those involving the retinoblastoma (Rb) protein. This disruption promotes uncontrolled cellular proliferation, contributing to malignant transformation. Research surrounding E7 has focused on its molecular interactions, mechanisms of action, and potential as a target for therapeutic interventions. Studies have demonstrated that E7 can evade the immune response, making it a candidate for vaccination strategies aimed at eliciting robust anti-tumor immune responses. Additionally, E7 is used as a biomarker for HPV-related cancers, enhancing early detection and diagnostic measures. With the growing incidence of HPV-associated cancers worldwide, understanding the biology of the E7 protein is essential for developing targeted therapies, improving vaccine effectiveness, and ultimately reducing the burden of these diseases. Ongoing research includes the development of E7-based immunotherapies and novel approaches to inhibit its oncogenic functions, with the aim of translating these findings into clinical applications that could benefit patients diagnosed with HPV-related cancers.
